Therapeutic agent tectochrysin inhibits macrophage signaling and reduces bone erosion and synovitis in rheumatoid arthritis, indicating new treatment possibilities.
Tectochrysin may be a novel RA therapeutic agent, likely acting via macrophage JAK/STAT pathway inhibition, with promising clinical potential.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: